GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

England’s cost effectiveness body NICE has recommended GSK’s new severe asthma treatment Nucala, reversing an earlier decision to reject it. Nucala (mepolizumab) is the first biologic ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...